Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032

Celcuity Inc., a clinical-stage biotechnology company, announced the pricing of an upsized $500 million convertible senior notes offering due 2032, increased from the previously announced $400 million. The company plans to use net proceeds of approximately $484.3 million to repay Oxford Finance debt and fund working capital, clinical trials, and R&D. The convertible notes carry a 0.250% interest rate with a conversion price of approximately $124.53 per share, representing a 40% premium to the stock price on June 3, 2026.

06/03/2026, 10:13 PM • GlobeNewswire

Why Celcuity Stock Popped on Monday

Celcuity stock rose nearly 4% after analyst Silvan Turkcan from Citizens initiated coverage with a 'market outperform' rating and $150 price target. The bullish outlook centers on gedatolisib, the company's investigational breast cancer drug, which is less than two months away from FDA review completion. The analyst highlighted the drug's potential for approval in multiple indications beyond breast cancer, which could significantly increase its value.

04/27/2026, 6:18 PM • The Motley Fool

Why Celcuity Stock Popped Today

Celcuity stock rose over 4% after releasing its 2025 financial results, beating analyst expectations with a narrower-than-expected net loss of $0.73 per share versus the projected $1.05. The clinical-stage biotech, which has no revenue, significantly improved its cash position to $166 million from $22.5 million at end-2024, providing substantial runway. The company is also anticipating phase 3 trial results for gedatolisib in advanced breast cancer treatment in Q2.

03/26/2026, 8:05 PM • The Motley Fool

Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug

Deerfield Management Company increased its stake in Celcuity by 980,470 shares (worth $80.6 million) in Q4, bringing its total position to $170.95 million. Celcuity's stock has surged 1,040% over the past year as the FDA accepted its new drug application for gedatolisib in breast cancer treatment with a decision date of July 17, 2026.

03/13/2026, 10:28 AM • The Motley Fool

Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology

Celcuity announced publication of Phase 3 VIKTORIA-1 trial results showing gedatolisib combined with palbociclib and fulvestrant reduced disease progression or death risk by 76% in HR+/HER2- advanced breast cancer patients with PIK3CA wild-type mutations. The FDA has granted Priority Review for gedatolisib's New Drug Application with a decision expected by July 17, 2026.

03/09/2026, 5:42 PM • GlobeNewswire

Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position

Perceptive Advisors purchased 203,881 shares of Celcuity (CELC) in Q4 2025 for approximately $16.76 million, bringing its stake to 5.62% of AUM and making it the fund's second-largest holding. The stock has surged 700% over the past year, driven by anticipation of FDA approval for the company's lead drug candidate Gedatolisib, which has a PDUFA goal date of July 17, 2026. The significant investment by a specialist biotech investor suggests conviction that major catalysts remain ahead.

02/22/2026, 2:05 PM • The Motley Fool

Soleus Adds a Significant Number of Celcuity Shares

Soleus Capital Management increased its stake in Celcuity by 629,398 shares, bringing its total holdings to over 1.8 million shares valued at $180.36 million. This purchase elevated Celcuity to Soleus's third-largest holding, representing 6.7% of the fund's AUM. The move signals bullish confidence in the clinical-stage biotech company, which has seen its stock surge 745% over the past year.

02/13/2026, 7:34 AM • The Motley Fool

Director Sells 20,000 Celcuity Shares for $2.4 Million Following 933% Share Price Jump

Celcuity director David Dalvey sold 20,000 shares indirectly for $2.4 million on January 27, 2026, representing 18.18% of his holdings. The sale occurred via a Rule 10b5-1 trading plan through Brightstone Venture Capital Fund. Despite the insider sale, Celcuity stock has surged 933% over the past year following positive clinical trial results for its breast cancer treatment, though the company remains unprofitable.

02/06/2026, 4:05 PM • The Motley Fool

3 Stocks You’ll Wish You Bought Before 2026

The article highlights three small-cap stocks that have shown impressive gains in 2025, including a biotech company, a fintech platform, and an online consignment store, each with unique market potential and growth trajectories.

12/04/2025, 4:47 AM • Investing

This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results

Apis Capital Advisors invested $38.3 million in Celcuity, acquiring 776,000 shares during Q3 2025, making it their largest holding. Celcuity, a clinical-stage biotech firm, has seen its stock surge 669% in a year following positive phase 3 results for its cancer drug gedatolisib.

11/27/2025, 5:22 PM • The Motley Fool

Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)

Celcuity reported promising Phase 1 clinical trial results for gedatolisib combined with darolutamide in metastatic castration-resistant prostate cancer, showing a 67% six-month progression-free survival rate and generally well-tolerated treatment.

10/18/2025, 4:30 AM • GlobeNewswire

Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial

Celcuity announced full enrollment of the PIK3CA mutant cohort in its Phase 3 VIKTORIA-1 clinical trial, with expected topline data in late Q1 or Q2 2026. Preliminary Phase 1b data showed promising median progression-free survival of 14.6 months for patients with PIK3CA-mutated advanced breast cancer.

10/18/2025, 4:30 AM • GlobeNewswire

Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer

Celcuity announced promising Phase 3 trial results for gedatolisib, a multi-target PAM inhibitor for advanced breast cancer, demonstrating significant improvements in progression-free survival and response rates compared to standard treatment.

10/18/2025, 4:30 AM • GlobeNewswire

Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments

Several biotech companies are developing innovative cancer treatments, with promising clinical trial results in various cancer types, focusing on immunotherapy and personalized medicine approaches.

07/29/2025, 3:46 PM • Benzinga

Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention

Cancer research companies are attracting investor interest as the oncology market is projected to grow significantly, with several firms showing promising clinical trial results and strategic developments in cancer treatments.

07/08/2025, 10:25 AM • Benzinga